Physician profile
John Rennie Blake
NPI 1447220363
$6,205.77
in general payments reported to CMS, 2019-2025
37 companies · $369 in 2025
The $369 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $896 · 2020: $784 · 2021: $1,098 · 2022: $999 · 2023: $1,139 · 2024: $921 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,428.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $731.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boston Scientific Corporation | $614.26 | 2022-2024 | Wavewriter Alpha Prime 16 |
| Astrazeneca Pharmaceuticals LP | $567.48 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $433.80 | 2022-2025 | |
| Amarin Pharma, INC. | $428.73 | 2019-2022 | |
| Lilly USA, LLC | $328.78 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Nevro Corp. | $290.48 | 2020-2023 | Senza |
| Merck Sharp & Dohme LLC | $275.44 | 2019-2021 | |
| Pfizer INC. | $269.65 | 2019-2023 | |
| Abbvie INC. | $248.53 | 2021-2024 | Vraylar |
| Sanofi-Aventis U.S. LLC | $240.82 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.48 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $156.00 | 2019-2024 | Veozah |
| Abbott Laboratories | $150.07 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $114.98 | 2019-2023 | Xarelto |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Blake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.